Aging is moving from an abstract scientific mystery toward something researchers can increasingly measure, manipulate and test. But that does not mean humanity has solved aging — or is only a year or two away from doing so.

The post above from Rand (@rand_longevity) is a useful jumping-off point for the bigger question: how close are we to actually solving biological aging? The answer depends on what “solving” means. Slowing one pathway, reversing one age-related disease, rejuvenating one tissue and making an entire human body biologically younger are four very different milestones.

The Biggest Change Is That Rejuvenation Has Entered Human Testing

The most important development right now is not a supplement, a longevity clinic or a mouse study. It is that a form of partial epigenetic reprogramming has entered a real human clinical trial.

Life Biosciences’ ER-100 uses controlled expression of three Yamanaka-related factors — OCT4, SOX2 and KLF4 — in an attempt to restore more youthful gene-expression patterns in retinal cells. In October 2026, the company reported interim Phase 1 results from three people with glaucoma. The treatment was well-tolerated through Day 56, and two participants showed preliminary improvements in visual-field testing. The trial is primarily designed to test safety and tolerability, not to prove that aging has been reversed. The study is registered as NCT07290244.

That is a major scientific milestone because it takes a rejuvenation concept out of cell culture and animal models and puts it into humans. But it is still one tissue, one disease category and an extremely early safety trial. Three participants are nowhere near enough to establish broad efficacy.

Why Partial Reprogramming Matters

Aging is partly associated with changes in the epigenome — the control system that helps determine which genes are active or silent. Partial reprogramming attempts to reset some of those patterns without pushing cells all the way back into an embryonic state.

A 2026 review in npj Aging describes partial reprogramming as one of the field’s most promising approaches while also stressing that it remains incompletely understood. Researchers still need to solve delivery, dosing, durability, cancer risk, genomic stability and the possibility that different tissues may require different rejuvenation strategies.

What Has Not Been Solved Yet

Human aging is not one switch. It is a network of interacting processes involving genomic damage, epigenetic drift, mitochondrial dysfunction, cellular senescence, stem-cell exhaustion, altered nutrient sensing, protein quality control, immune changes and tissue-level remodeling.

That is why a therapy that makes retinal cells behave more youthfully does not automatically imply that the same treatment can rejuvenate the heart, brain, kidneys, immune system and skeletal muscle safely at the same time.

The U.S. Food and Drug Administration still states that no medication has been proven to slow or reverse the aging process. That is the clearest reality check against headlines suggesting aging is already effectively cured.

So How Close Are We?

For reversing specific age-related damage in specific tissues, we may be entering the first credible human-test era right now. ER-100 is an example of that transition.

For slowing multiple biological aging pathways at once, the field is probably in an intermediate stage: many mechanisms are known, many interventions work in animals, and some are being tested in humans, but no single therapy has demonstrated robust whole-body age reversal.

For reliably reversing whole-body human aging, we are not close enough to responsibly name a year. The remaining problems include delivery to every relevant tissue, controlling cancer risk, proving long-term durability, validating biomarkers, determining whether rejuvenated cells retain their identity, and running trials long enough to show meaningful health outcomes.

AI Could Speed the Timeline Without Eliminating Biology

AI can accelerate drug discovery, protein design, biomarker analysis, target selection and interpretation of large biological datasets. It may shorten the time required to identify promising interventions. But AI cannot skip the hardest part: proving that a therapy is safe and effective inside real human bodies over time.

That is why aggressive predictions such as “AGI will solve aging in a few years” should be treated as hypotheses, not schedules. The bottleneck is no longer just generating ideas. It is validating them biologically and clinically.

The Most Reasonable Outlook

The next several years could be extremely important. If epigenetic-reprogramming trials continue to show acceptable safety and real functional benefit, the field may progress from treating one localized age-related condition toward testing rejuvenation across additional tissues.

That would still be far short of “ending aging,” but it would represent something historically new: medicine deliberately restoring youthful cellular function rather than only treating downstream diseases after damage accumulates.

So the best answer today is this: we are much closer to treating pieces of aging than we are to solving aging as a whole. The gap between those two statements is where the next decade of longevity science will be decided.

Editor’s Note: This article discusses emerging longevity research and is not medical advice. The ER-100 data cited above are early Phase 1 findings from three participants and should not be interpreted as proof of human age reversal.